Doxylamine/pyridoxine transdermal patch - Aequus Pharmaceuticals
Alternative Names: AQS-1303; Doxylamine succinate/pyridoxine hydrochloride - Aequus Pharmaceuticals; Pyridoxine/doxylamine transdermal patchLatest Information Update: 28 Sep 2020
At a glance
- Originator Aequus Pharmaceuticals
- Class Antiemetics; Picolines; Pyridines; Sedating antihistamines; Small molecules; Vitamins
- Mechanism of Action Biogenic monoamine uptake modulators; Histamine H1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Nausea and vomiting
Highest Development Phases
- No development reported Nausea and vomiting
Most Recent Events
- 28 Sep 2020 No recent reports of development identified for clinical-Phase-Unknown development in Nausea and vomiting in Canada (Transdermal, Patch)
- 17 Dec 2018 Corium International has been acquired by Gurnet point capital
- 29 Nov 2018 Aequus Pharmaceuticals announces intention to launch Doxylamine/pyridoxine transdermal patch in Europe, on the basis of approved oral reference product, Diclectin, for the treatment of Nausea and vomiting